Market Capitalization

Pearl Studio, the force behind Kung Fu Panda 3, is set to release a new animated epic. Can this modern take on ancient folklore conquer the world?

With shareholder backing and a major acquisition nearly complete, IsoEnergy is building a global uranium powerhouse to meet soaring nuclear energy demand.

Ridgewood Infrastructure's acquisition of Dauntless Air isn't just a deal; it's a bet on a new class of essential assets fueled by climate change and tech.

Frasers Group's €1.98 billion offer for Hugo Boss is more than a deal; it's a strategic gambit that tests the value of a legacy German brand.

Amid a crisis in higher education, Abilene Christian University's top financial grade offers a masterclass in strategic resilience and sustainable operations.

Oxford Commercial Finance's milestone isn't just a number; it's a sign of a deep shift. As traditional banks step back, who is funding America's growth?

OneAscent Investments crosses $1B in faith-aligned ETFs, signaling a shift in investor priorities. But does performance match principle in this growing niche?

A major financial outlook warns that geopolitical fragmentation, stubborn inflation, and a new AI arms race are creating a new reality for investors.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

Swedish freight-tech leader Einride's explosive Nasdaq debut validates a ten-year mission to build the resilient, autonomous future of supply chains.

A new partnership reveals a critical shift in engineering. As AI pushes data centers to their thermal limits, companies are abandoning physical prototypes for digital simulation.

A record $663M month for one lender reveals a deeper story about America's future: a radical transformation of our cities, one complex deal at a time.

Soaring healthcare costs, fueled by GLP-1 drugs, have employers trapped. A new report shows why flexible benefits are becoming a critical survival strategy.

New research reveals a shocking 53-point gap between leaders who think their teams are AI-ready and employees who feel completely unprepared.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

evyAI is offering its full AI sales agent for free until summer 2026, challenging the subscription model. We dig into the strategy, the risks, and what it means for you.

The asset manager's May report reveals $3.3B in net inflows, driven by a major target date fund win, underscoring its market resilience and leadership.

CIBC's new SpaceX CDR offers Main Street a ticket to the final frontier of investing. But is it a leap for investor democracy or a step into the unknown?

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

A global health giant is now targeting the world's financial system, arguing that crippling debt is a deadlier crisis than any disease. Is their plan a revolution or a fantasy?